Dystrophin Protein Expression

Biomarker

Also known as: dystrophin protein expression

Related News

FDA Grants Fast Track Designation to Precision BioSciences' DMD Gene Therapy

Mar 09, 2026

Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy designed to treat patients with mutations in exons 45-55.

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD Gene Editing Therapy

Mar 09, 2026

Precision BioSciences announced FDA Fast Track designation for PBGENE-DMD, a first-in-class gene editing therapy for Duchenne muscular dystrophy targeting mutations in exons 45-55, representing up to 60% of DMD patients.